Page 74 | Certara

Fact Sheet

Attain FDA Label Claims for Kinase Inhibitor Drugs with the Simcyp™ Simulator

Simcyp was used by pharma and biotech companies to inform, reduce and/or replace clinical studies…

CertaraDecember 6, 2023

Press Coverage

Pharma Focus Europe – Issue 03 – Using AI to Accelerate Drug Development

Authors: Professor Amin Rostami-Hodjegan, Professor Piet van der Graaf This Pharma Focus EU article, co-authored…

CertaraDecember 5, 2023

Announcement

Certara Launches Updated Version of Pirana Modeling Workbench

PRINCETON, N.J.— December 1, 2023 – Certara, Inc., a global leader in biosimulation, today announced…

CertaraDecember 1, 2023

Publication

Model-informed target identification and validation through combining quantitative systems pharmacology with network-based analysis

Authors: Vijayalakshmi Chelliah, Piet H. van der Graaf One of the main areas where quantitative…

CertaraNovember 28, 2023

Publication

Creation of novel sensitive probe substrate and moderate inhibitor models for a comprehensive prediction of CYP2C8 interactions for tucatinib

Authors: Ian E. Templeton, Karen Rowland-Yeo, Hannah M. Jones, Christopher J. Endres, Ariel R. Topletz-Erickson, Hao Sun, Anthony J. Lee A…

CertaraNovember 28, 2023

Press Release

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex…

CertaraNovember 21, 2023

White Paper

European Collaboration on Health Technology Assessment(HTA): The New Road to Access

CertaraNovember 21, 2023

Publication

A quantitative clinical pharmacology-based framework for model-informed vaccine development

Historically, vaccine development and dose optimization have followed mostly empirical approaches without clinical pharmacology and…

CertaraNovember 20, 2023

Blog

Key Lessons from the 2nd Annual FDA ASCO WORKSHOP on Getting the Dosage Right: Optimizing Dosage Selection Strategies in Combination Cancer Therapies

Cancer treatment has evolved from generally cytotoxic therapies towards drugs that target specific pathways and…

CertaraNovember 17, 2023

Publication

No Recipe for Quantitative Systems Pharmacology Model Validation, but a Balancing Act Between Risk and Cost

Quantitative systems pharmacology (QSP) models generate predictions by formalizing biological understanding and integrating multiscale data,…

CertaraNovember 16, 2023

Attain FDA Label Claims for Kinase Inhibitor Drugs with the Simcyp™ Simulator

Pharma Focus Europe – Issue 03 – Using AI to Accelerate Drug Development

Certara Launches Updated Version of Pirana Modeling Workbench

Model-informed target identification and validation through combining quantitative systems pharmacology with network-based analysis

Creation of novel sensitive probe substrate and moderate inhibitor models for a comprehensive prediction of CYP2C8 interactions for tucatinib

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

European Collaboration on Health Technology Assessment(HTA): The New Road to Access

A quantitative clinical pharmacology-based framework for model-informed vaccine development

Key Lessons from the 2nd Annual FDA ASCO WORKSHOP on Getting the Dosage Right: Optimizing Dosage Selection Strategies in Combination Cancer Therapies

No Recipe for Quantitative Systems Pharmacology Model Validation, but a Balancing Act Between Risk and Cost

Newsletter sign up

Quick links

Solutions

Contact